🇺🇸

US SEC Filing Intelligence

· daily

US Corporate Distress Financial Stress SEC Filings — July 29, 2026

All five filings in this digest are Nasdaq/NYSE listing deficiency notices, creating a concentrated thematic cluster of micro-cap and distressed equities facing imminent delisting. The common thread is a severe erosion of market confidence, with each company failing to maintain either minimum bid price ($1.00) or minimum market value of listed securities ($1M-$50M thresholds). The period-over-period data, while not explicitly provided in the filings, is implied by the 30-consecutive-day trading patterns that triggered the notices, suggesting sustained price declines. No insider trading activity, capital allocation changes, or forward-looking guidance were reported in these 8-Ks, which is notable as it signals management may be in a reactive, rather than proactive, stance. The most critical development is the simultaneous clustering of four new deficiency notices within a single week (July 22-24, 2026), suggesting a broader market rotation away from speculative, pre-revenue, or cash-burning business models. The market implication is clear: investors should expect a wave of over-the-counter (OTC) migrations or reverse stock splits as these companies scramble to maintain exchange listings, with SCWorx and Loop Industries facing the most acute multi-factor compliance challenges.

5 high priority 5 total filings
· daily

Global High-Priority Regulatory Events — July 29, 2026

This digest covers 50 filings from July 29, 2026, dominated by Indian M&A, insolvency, and regulatory actions, alongside several US SPAC business combinations and Nasdaq delisting notices. A key trend is the high volume of open offers and structured acquisitions in India (Niraj Cement, Duke Offshore, 5Paisa Capital), while US markets show significant SPAC activity (Westin Acquisition, PBT Land & Minerals) and two capital market withdrawals (Astral demerger, EFC scheme). Insider activity is sparse but notable in the US, including the dilution of existing Processa stockholders (to ~0.9% ownership), signaling extreme risk. Negative signals are concentrated: MT Educare, K-Lifestyle, and ICSA India are deep in insolvency with ongoing defaults; three US companies (SCWorx, Foxx Development, Celularity) received Nasdaq deficiency notices. Unusually, a major impersonation incident was reported in a CoC meeting (K-Lifestyle). On the positive side, significant capital raisings (Processa $200M, Catalyst Acquisition $200M), strategic re-routing (RPG Life Sciences restructuring with a $700M growth fund), and a transformative healthcare SPAC merger (Westin/FCHS) offer high-upside opportunities. The key recommendation is to avoid deeply distressed Indian insolvencies and watch for delisting catalysts in the US, while selectively targeting the structured exits and operational restructurings.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — July 29, 2026

Today's digest (July 29, 2026) reveals a market sharply bifurcated between AI/infrastructure winners and legacy industrials facing headwinds. The standout theme is surging data center demand, with Vertiv, Generac, and Teradyne all posting exceptional results and raising guidance, while SK hynix reported a record quarterly operating profit up 557% YoY. However, this strength contrasts with weakness in traditional sectors: Ford swung to a net loss, Clarivate took a massive goodwill impairment, and ArcBest reported a GAAP loss despite revenue growth. Capital allocation patterns show aggressive share repurchases at SiteOne ($114M in H1) and debt reduction at Clarivate ($211M), while insider activity is notably absent from today's filings. The most significant corporate action is Criteo's redomiciliation from France to Luxembourg, with a planned move to the U.S. in January 2027, aiming for index inclusion. The PBT Land & Minerals S-4 filing outlines a complex restructuring of the Permian Basin Royalty Trust, converting a 75% net overriding royalty into a cost-free 15% royalty, which could dramatically improve cash flow predictability. Overall, the data suggests a 'two-speed' economy where AI infrastructure investment is a powerful tailwind for select companies, while consumer-facing and industrial names face margin pressure and demand uncertainty.

10 high priority 40 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — July 29, 2026

The 17 filings for the S&P 500 Consumer Discretionary sector reveal a sector bifurcating between companies executing well in a challenging environment and those facing significant headwinds. A clear theme is margin compression, with 4 out of 5 major operators (Chipotle, MGM, O'Reilly, Carvana) reporting contracting margins despite revenue growth, driven by rising labor, food, and marketing costs. However, top-line growth remains robust for select names, with Carvana (+52% YoY revenue) and Chipotle (+18.2% YoY) leading. The automotive sub-sector is flashing major warning signs: Ford reported a Q2 net loss and a 43% drop in H1 operating cash flow, while a coordinated insider selling wave at General Motors saw the CEO and President sell over $16M in stock. In contrast, Starbucks showed a strong earnings recovery (+86% GAAP EPS) driven by its China divestiture and raised full-year guidance. Capital allocation is a key differentiator, with O'Reilly aggressively buying back $2.43B in H1 2026, while MGM and Starbucks are using proceeds for debt reduction. The most critical development is the divergence in the auto sector, where Ford's deteriorating cash position and GM's insider selling suggest deep structural challenges ahead.

10 high priority 7 medium 17 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — July 29, 2026

The S&P 500 Healthcare sector is showing a clear bifurcation between growth and profitability in Q2 2026. While top-line growth remains robust across several companies—Humana's revenue surged 26.2% YoY, Boston Scientific grew 7.5%, and Biogen's Growth Portfolio expanded 24%—earnings quality is deteriorating sharply. Biogen's GAAP net income plunged 85% due to acquisition-related charges, and Humana's adjusted EPS guidance implies a ~47.5% decline from FY2025, signaling that deal costs and rising R&D are compressing margins. Capital allocation is mixed: Centene is proactively deleveraging with a $500M debt redemption, while J&J is investing aggressively in M&A (Firefly Bio, Sail Biomedicines) at the cost of a $0.64 EPS hit in 2026. Insider activity is muted and largely neutral, with only small tax-related sales at Medtronic and Intuitive Surgical, offering no strong conviction signals. The overarching theme is that revenue growth is being purchased at the expense of near-term profitability, creating a challenging environment for earnings-driven investors.

5 high priority 5 medium 10 total filings
· daily

US Earnings Financial Results SEC Filings — July 29, 2026

The 50 filings for the period ended June 30, 2026, reveal a market characterized by a sharp divergence between top-line growth and bottom-line quality. While a majority of companies reported revenue increases (e.g., Omnicom +100%+, Cadence +24%, Coca-Cola +7%), profitability was often undermined by rising operating costs, impairment charges, and aggressive capital allocation. A significant theme is the 'cash burn for growth' pattern, where companies like Biogen ($5.1B acquisition), GE HealthCare ($2.3B in acquisitions), and Cadence ($2.1B in acquisitions) are depleting cash reserves to fund M&A, while simultaneously engaging in massive share buybacks (Omnicom $2.99B, Waste Management $1B, Masco $592M). This has led to a deterioration in balance sheet strength for several firms, with negative equity positions (Masco, Verisk) and widening net losses (Clarivate, MGP Ingredients, Ford). The technology sector shows strong subscription/SaaS growth (Commvault +39% SaaS revenue), while industrial and consumer-facing companies face margin compression and inventory build-ups (VF Corp +38.5% inventory). Insider trading activity is notably absent from the enriched data, but the forward-looking statements and capital allocation decisions provide clear signals of management's strategic priorities. The most critical developments are the wave of transformative M&A and the aggressive use of debt and cash for shareholder returns, which creates both opportunities for earnings accretion and risks of financial distress.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — July 29, 2026

The eight DEF 14A filings for the 2026 proxy season reveal a governance landscape dominated by capital structure maneuvers and insider control dynamics, rather than broad-based executive compensation trends. The most critical development is at Earth Science Tech, where a CEO with 43% common stock ownership and all super-voting Series B Preferred shares seeks shareholder authorization to negotiate his own buyout, creating a profound conflict of interest. Quantum Corporation stands out with a positive narrative of debt elimination and revenue improvement, contrasting with the cash-centric, dilutive concerns at Earth Science Tech. A significant trend is the prevalence of share increase and incentive plan amendments, with Replimune seeking to double its authorized shares and Powerfleet adding 8.4 million shares to its incentive plan, suggesting a broad need for equity currency. The SPAC Alchemy Investments is racing against a September 2026 deadline to close its business combination with Cartiga, LLC, introducing a binary catalyst. Overall, the filings indicate a market where management is seeking more equity flexibility, while investors must scrutinize governance proposals that could significantly dilute or entrench existing control.

8 high priority 8 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 29, 2026

The IPO pipeline on July 29, 2026, is dominated by a mix of de-SPAC transactions, direct listings, and distressed capital raises, with a notable concentration in the energy and technology sectors. Key period-over-period trends are absent from most filings due to the lack of historical operating data for pre-revenue or development-stage companies, but several filings reveal severe financial distress—Global Interactive Technologies has a going concern opinion and only ~4 months of cash runway, while Moleculin Biotech warns of capital only into Q1 2027 without the maximum offering. The most critical development is the PBT Land & Minerals business combination, which converts a 75% net overriding royalty interest into a cost-free 15% royalty, eliminating cost exposure and providing more predictable cash flow, backed by a $71.2M backstop from SoftVest and Horizon Kinetics. Insider activity is minimal across filings, but the lack of insider selling in the PBT deal and the presence of a backstop commitment signal institutional confidence. Portfolio-level patterns include a trend toward alternative listing methods (direct listing, rights offerings) and a high proportion of companies with going concern or liquidity warnings, suggesting a bifurcated pipeline with both high-quality asset conversions and distressed issuers.

10 high priority 10 total filings
· daily

US SEC Trading Suspension Halt Orders — July 29, 2026

On July 29, 2026, five US-listed companies disclosed trading suspension risks from Nasdaq and NYSE, all driven by market value and bid price deficiencies. The cluster reveals a severe micro-cap liquidity crisis, with four companies (SCWorx, Foxx Development, Celularity, Loop Industries) facing Nasdaq delisting and one (LiveWire Group) under NYSE scrutiny. No period-over-period revenue or margin data was available in these filings, but the uniform negative sentiment (5/5 filings) and lack of insider buying or capital allocation actions signal a systemic erosion of market confidence. The most critical development is the concentration of compliance deadlines in January 2027, creating a binary catalyst for each stock. The pattern suggests a broader sell-off in low-float, cash-burning small caps, with no company demonstrating a credible turnaround plan.

5 high priority 5 total filings
· daily

US Executive Officer Management Changes SEC — July 29, 2026

This digest of 36 filings reveals a period of significant leadership transitions across the US equity landscape, with a notable number of CFO changes and board refreshments. Key themes include a wave of insider equity actions (accelerated vesting, enhanced severance) to retain talent, and a mixed earnings season where companies like Fortrea and Stepan show operational turnarounds while others like Adaptive Biotechnologies and VF Corp navigate mixed results. The most critical developments are the CFO transitions at Lemonade, Owens Corning, and Clarivate, which create both execution risk and potential opportunity. Portfolio-level patterns show a clear bifurcation: companies with strong period-over-period growth (Dynatrace, Adaptive Biotechnologies) are investing in AI leadership, while those with declining metrics (VF Corp, Kohl's) are undergoing board refreshment. The data suggests a market favoring companies with clear strategic direction and operational discipline, as evidenced by the positive sentiment around appointments of AI and technology experts to boards.

36 high priority 36 total filings
· daily

US Corporate Board Director Changes SEC Filings — July 29, 2026

This USA Board Room Changes digest covers 36 filings, with 31 newly published since the last brief. The dominant theme is orderly leadership succession and board refreshment, with 15+ director/officer changes including several high-profile appointments (e.g., AI expert Chandu Thota to Dynatrace, Anthropic's Paul Smith to Humana). A notable sub-theme is the intersection of board changes with financial performance: several companies announcing leadership transitions also reported mixed Q2 results, with VF Corp, Fortrea, and Stepan showing improving trends, while Adaptive Biotechnologies and Wolfspeed face strategic pivots. Insider activity is limited, but the CFO transition at Lemonade (Bixby to Board, Stead as CFO) and the CEO succession at Dakota Gold (Quartermain to Henris) signal planned transitions. Capital allocation is modest, with only Tronox and Schneider National declaring dividends. The most actionable signals come from companies where board changes coincide with raised guidance (VF Corp, Fortrea) or strategic separation plans (Adaptive Biotechnologies).

36 high priority 36 total filings
· daily

USA Insider Trading Pulse — July 29, 2026

Today's insider trading pulse reveals a pronounced bearish tilt, with 22 sell transactions against only 5 buys, concentrated heavily in financials and industrials. The most significant event is a massive $148M secondary sale by Advent International in Intuitive Machines, signaling a potential top in the space-tech sector. A cluster of CFO and C-suite sales in regional banks (Commerce Bancshares, Old National, WesBanco) suggests management is pricing in margin pressure from the current rate environment. On the bullish side, coordinated director buying in Nano-X Imaging ($53K combined) and a $100K purchase by a director at Grupo Aeromexico stand out as high-conviction signals in beaten-down names. The data also shows a wave of stock awards at Kennametal and Dillard's, which are neutral but indicate ongoing retention efforts. The overall picture is one of insider caution, with selling 4x the volume of buying, warranting a defensive posture in financials and recently high-flying growth names.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — July 29, 2026

The July 29, 2026, US M&A stream reveals a bifurcated SPAC market: high-quality, well-capitalized deals (Westin/FCHS, Processa/Vidya) are proceeding, while others face massive shareholder redemptions (Inflection Point/Air Water at 24.7M shares, D. Boral/Exascale at 95.95% of public shares), signaling acute investor skepticism toward blank-check vehicles with uncertain targets. The Processa-Vidya acquisition stands out as a transformative, high-conviction biotech deal backed by a $200M PIPE, though existing shareholders face extreme dilution to ~0.9% ownership. On the capital formation side, Catalyst Acquisition Corp. successfully priced a $200M IPO targeting media/gaming, while Rising Dragon issued a small extension note to avoid liquidation. Period-over-period comparisons are limited in these event-driven filings, but the aggregate redemption data (two SPACs seeing >95% public exit) points to a systemic trust crisis in the SPAC structure. The lone non-SPAC deal, Medalist Diversified REIT's $5.8M property acquisition, represents a small, conservative real estate investment with no debt. Overall, the stream signals that only deals with strong strategic rationale and committed PIPE financing are likely to close, while weak SPACs face a 'show me the money' moment from public shareholders.

11 high priority 11 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 29, 2026

Overnight filings reveal a bifurcated market with explosive growth in AI-driven industrial and semiconductor names (Vertiv, SK hynix, Teradyne) contrasting with significant distress in legacy automotive (Ford) and data/information services (Clarivate). Insider activity is a key signal, with a massive $35M purchase at Scribe Therapeutics and a $149K director buy at MapLight Therapeutics signaling strong conviction, while a CEO sale at Accelerant Holdings under a 10b5-1 plan is a less concerning signal. Capital allocation trends show aggressive share repurchases at SiteOne Landscape Supply and debt reduction at Clarivate, while Ford's cash burn is a major red flag. Guidance changes are overwhelmingly positive, with Constellium, Vertiv, and Generac all raising full-year outlooks, pointing to sustained demand in data centers and infrastructure. The most critical development is the record performance in the semiconductor and data center supply chain, which is driving a wave of positive revisions and insider confidence.

17 high priority 33 medium 50 total filings
· daily

Biotech Small-Cap Approvals — July 28, 2026

This digest covers 7 FDA approvals from July 22-24, 2026, with a mix of 0 NMEs, 0 biosimilars, 0 label expansions, and 7 'Other' approvals, yielding 4 bullish and 3 neutral signals. The period lacks a dominant therapeutic area theme, as approvals span neurology (centanafadine, edaravone), oncology (bevacizumab-vikg, fludarabine phosphate, zidesamtinib), and pain (naproxen sodium/acetaminophen). The highest-conviction signal is the NME approval of centanafadine (SIMTRIYO) by Otsuka Pharmaceutical, which received Priority Review for an undisclosed indication, suggesting strong unmet need and commercial potential. A key risk is the lack of commercial data (peak sales, pricing, exclusivity) across all approvals, making valuation assessments highly speculative. The period also includes two biosimilar approvals (fludarabine phosphate by Hisun Pharm, edaravone by Zydus Pharms) and one label expansion (naproxen sodium/acetaminophen by Kenvue), which are neutral signals with limited near-term investment impact.

7 total filings
· daily

NME Blockbuster Approvals — July 28, 2026

This single-approval period is dominated by Otsuka Pharmaceutical's NME approval of centanafadine (SIMTRIYO) for an undisclosed indication, a Priority Review designation that signals FDA recognition of significant unmet need. With no biosimilar or label expansion activity, the digest highlights a high-conviction bullish signal for Otsuka, though the absence of disclosed peak sales estimates, pricing power, or market position data limits full commercial assessment. The key risk is the lack of detail on exclusivity and indication size, which investors must monitor for revenue potential. This approval underscores Otsuka's NME execution capability, but the single-event period offers limited sector-wide thematic clustering.

1 total filings
· daily

Orphan Drug Approvals — July 28, 2026

This digest covers two FDA approvals from July 22-23, 2026, both classified as 'FALLBACK' type but carrying bullish signals for their respective sponsors. The period saw zero NMEs, zero biosimilars, and zero label expansions, with both approvals falling under 'Other' category—one being a label expansion for MACIMORELIN ACETATE (AETERNA ZENTARIS) and the other an NME/Orphan approval for ZIDESAMTINIB (NUVALENT INC). The dominant therapeutic area theme is not clearly defined due to the limited dataset, but the highest-conviction signal is the NME approval of ZIDESAMTINIB (JIDEYTRO) by NUVALENT INC, which carries Orphan Drug designation and represents a significant pipeline validation for the sponsor. Key risks include the lack of disclosed commercial data (peak sales, pricing power, market position) for both drugs, limiting near-term revenue visibility for investors. No biosimilar approvals were recorded, so no originator erosion signals are present.

2 total filings
· daily

New Drug Approvals (Original) — July 28, 2026

This digest covers 7 FDA approvals from July 22-24, 2026, comprising 3 NMEs (Centanafadine by Otsuka, Bevacizumab-vikg by Outlook Therapeutics, Zidesamitinib by Nuvalent), 3 biosimilars (Fludarabine by Hisun, Edaravone by Zydus, Verapamil by Knack), and 1 label expansion (Naproxen Sodium/Acetaminophen by Kenvue). The dominant theme is oncology/neurology NME acceleration, with two novel agents (Zidesamitinib, Centanafadine) receiving priority or orphan designations. The highest-conviction signal is Zidesamitinib (JIDEYTRO) from Nuvalent Inc—an NME with Orphan Drug designation, signaling a potential precision oncology blockbuster with 7-year exclusivity and premium pricing potential. Key risk: all three NMEs lack disclosed peak sales estimates, pricing, or exclusivity details, creating commercial uncertainty for investors.

7 total filings